This trial seeks to compare the effects of melatonin supplementation versus placebo in subjects with the metabolic syndrome.
The primary purpose of this Phase II crossover design trial is to examine the safety and efficacy of 8mg of melatonin taken one hour before bedtime compared to a placebo treatment to improve at least one of the five components associated with the metabolic syndrome.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
39
Emory Hospital
Atlanta, Georgia, United States
Emory University
Atlanta, Georgia, United States
Metabolic Syndrome Components
Time frame: 3 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.